Hilda A Pickett Selected Research

Neoplasms (Cancer)

1/2022	Targeting telomeres: advances in telomere maintenance mechanism-specific cancer therapies.
1/2022	A DNA-fiber protocol for single molecule analysis of telomere (SMAT) length and extension events in cancer cells.
1/2021	Targeted Therapy of TERT-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy.
1/2020	Mechanisms that drive telomere maintenance and recombination in human cancers.
12/2019	FANCM suppresses DNA replication stress at ALT telomeres by disrupting TERRA R-loops.
10/2019	Telomerase promotes formation of a telomere protective complex in cancer cells.
1/2019	Enhanced cardiac repair by telomerase reverse transcriptase over-expression in human cardiac mesenchymal stromal cells.
1/2019	The FANCM-BLM-TOP3A-RMI complex suppresses alternative lengthening of telomeres (ALT).
1/2018	Telomere sequence content can be used to determine ALT activity in tumours.
9/2017	Functional dissection of breast cancer risk-associated TERT promoter variants.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hilda A Pickett Research Topics

Disease

23	Neoplasms (Cancer) 01/2022 - 03/2002
3	Bone Marrow Failure Disorders 01/2022 - 10/2014
3	Carcinogenesis 01/2017 - 03/2009
2	Neuroblastoma 01/2021 - 01/2016
2	Leukemia 01/2020 - 04/2009
2	Fanconi Anemia (Fanconi's Anemia) 12/2019 - 01/2019
1	Pulmonary Fibrosis (Fibrosing Alveolitis) 12/2021
1	Dyskeratosis Congenita (X-Linked Dyskeratosis Congenita) 12/2021
1	Acute Erythroblastic Leukemia (Erythroleukemia) 01/2020
1	Anemia 01/2020
1	Cicatrix (Scar) 01/2019
1	Myocardial Infarction 01/2019
1	Melanoma (Melanoma, Malignant) 11/2017
1	Carcinoma (Carcinomatosis) 06/2015
1	Chromosomal Instability (Chromosome Stability) 01/2014
1	Genomic Instability 01/2014

Drug/Important Bio-Agent (IBA)

18	Telomerase (Telomerase Reverse Transcriptase)IBA 01/2022 - 03/2002
5	Proteins (Proteins, Gene)FDA Link 01/2022 - 12/2011
5	EnzymesIBA 01/2018 - 04/2009
4	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 04/2009
3	A-Form DNA (A-DNA)IBA 01/2022 - 01/2013
1	Antineoplastic Agents (Antineoplastics)IBA 01/2022
1	tert-butylserineIBA 01/2022
1	1,1'- ((4,4,7,7- tetramethyl)- 4,7- diazaundecamethylene)bis- 4- (3- methyl- 2,3- dihydro(benzo- 1,3- oxazole)- 2- methylidene)quinolinium (YOYO)IBA 01/2022
1	Danazol (Azol)FDA LinkGeneric 12/2021
1	Proteasome InhibitorsIBA 01/2021
1	carfilzomibIBA 01/2021
1	OTX015IBA 01/2021
1	Glycophorins (Glycophorin C)IBA 01/2020
1	telomerase RNA (bTR)IBA 01/2019
1	Mitogen-Activated Protein KinasesIBA 11/2017
1	Phosphotransferases (Kinase)IBA 11/2017
1	LuciferasesIBA 09/2017
1	Estrogens (Estrogen)FDA Link 09/2017
1	RNA (Ribonucleic Acid)IBA 01/2016
1	Messenger RNA (mRNA)IBA 01/2016
1	RNA Splice SitesIBA 06/2015
1	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 06/2015
1	Tripeptidyl-Peptidase 1IBA 10/2014
1	MicronutrientsIBA 01/2014
1	Biomarkers (Surrogate Marker)IBA 01/2014
1	Folic Acid (Vitamin M)FDA LinkGeneric 01/2014
1	Estrogen ReceptorsIBA 04/2013
1	7- O- (2,6- dideoxy- 2- fluorotalopyranosyl)daunomycinoneIBA 01/2012
1	RibonucleoproteinsIBA 04/2009

Therapy/Procedure

4	Therapeutics 01/2022 - 01/2017
2	Drug Therapy (Chemotherapy) 01/2020 - 03/2002
1	Transplantation 01/2019